David A. Siegel Point Biopharma Global Inc. Transaction History

Two Sigma Advisers, LP

  • $41.3 Billion
  • Q3 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 14, 2023
SELL
$6.67 - $9.71 $950,475 - $1.38 Million
-142,500 Reduced 87.58%
20,200 $134,000
Q2 2023

Aug 14, 2023
BUY
$6.86 - $10.86 $764,890 - $1.21 Million
111,500 Added 217.77%
162,700 $1.47 Million
Q1 2023

May 15, 2023
BUY
$6.78 - $8.1 $347,136 - $414,720
51,200 New
51,200 $372,000

Others Institutions Holding PNT

# of Institutions
1
Shares Held
20K
Call Options Held
0
Put Options Held
0
View Full List

About POINT Biopharma Global Inc.

PNT Quotes by TradingView
  • Ticker PNT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 104,025,000
  • Description
  • POINT Biopharma Global Inc., a radiopharmaceutical company, focuses on the development and commercialization of radioligands that fight cancer. Its lead product candidates include PNT2002, a prostate-specific membrane antigen (PSMA) targeted radioligand that is in Phase III trial for the treatment of metastatic castration-resistant prostate canc...
More about PNT
Track David A. Siegel's Portfolio

Track David A. Siegel Portfolio

Follow David A. Siegel (Two Sigma Advisers, LP) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email